

Crystal data

$C_{21}H_{25}N$
 $M_r = 291.42$
 Monoclinic
 $P2_1/n$
 $a = 14.939(3) \text{ \AA}$
 $b = 6.078(4) \text{ \AA}$
 $c = 19.740(2) \text{ \AA}$
 $\beta = 102.345(12)^\circ$
 $V = 1750.9(11) \text{ \AA}^3$
 $Z = 4$
 $D_x = 1.106 \text{ Mg m}^{-3}$
 D_m not measured

Cu $K\alpha$ radiation
 $\lambda = 1.54184 \text{ \AA}$
 Cell parameters from 25 reflections
 $\theta = 27\text{--}29^\circ$
 $\mu = 0.475 \text{ mm}^{-1}$
 $T = 240 \text{ K}$
 Plate
 $0.50 \times 0.40 \times 0.05 \text{ mm}$
 Colourless

Data collection

Rigaku AFC-7R diffractometer
 2θ - ω scans
 Absorption correction: none
 2706 measured reflections
 2595 independent reflections
 2224 reflections with $I > 2\sigma(I)$

$R_{\text{int}} = 0.086$
 $\theta_{\text{max}} = 60^\circ$
 $h = 0 \rightarrow 16$
 $k = 0 \rightarrow 6$
 $l = -22 \rightarrow 21$
 3 standard reflections every 150 reflections
 intensity decay: -0.22%

Refinement

Refinement on F^2
 $R[F^2 > 2\sigma(F^2)] = 0.049$
 $wR(F^2) = 0.153$
 $S = 1.041$
 2595 reflections
 200 parameters
 H atoms not refined
 $w = 1/[\sigma^2(F_o^2) + (0.1034P)^2 + 0.2489P]$
 where $P = (F_o^2 + 2F_c^2)/3$

$(\Delta/\sigma)_{\text{max}} = 0.062$
 $\Delta\rho_{\text{max}} = 0.192 \text{ e \AA}^{-3}$
 $\Delta\rho_{\text{min}} = -0.184 \text{ e \AA}^{-3}$
 Extinction correction: *SHELXL93*
 Extinction coefficient: 0.0028 (6)
 Scattering factors from *International Tables for Crystallography* (Vol. C)

Table 1. Selected geometric parameters (\AA , $^\circ$)

N1—C1	1.144 (2)	C1—C2	1.443 (2)
C4—C5—C6	117.67 (14)	C10—C11—C12	116.91 (14)
C9—C8—C13	117.32 (14)		

Data collection: *MSCIAFC Diffractometer Control Software* (Molecular Structure Corporation, 1992a). Cell refinement: *MSCIAFC Diffractometer Control Software*. Data reduction: *TEXSAN* (Molecular Structure Corporation, 1992b). Program(s) used to solve structure: *SHELXS86* (Sheldrick, 1985). Program(s) used to refine structure: *SHELXL93* (Sheldrick, 1993). Molecular graphics: *TEXSAN*. Software used to prepare material for publication: *SHELXL93*.

Supplementary data for this paper are available from the IUCr electronic archives (Reference: OA1062). Services for accessing these data are described at the back of the journal.

References

- Chu, Y.-C., Tsang, T., Rahimzadeh, E. & Yin, L. (1988). *Phys. Status Solidi A*, **105**, K1–6.
- Gray, G. W. (1998). *Liq. Cryst.* **24**, 5–13.
- Hanemann, T., Haase, W., Svoboda, I. & Fuess, H. (1995). *Liq. Cryst.* **19**, 699–702.
- Hasse, W., Loub, J. & Paulus, H. (1992). *Z. Kristallogr.* **202**, 7–16.
- Hasse, W., Paulus, H. & Pendzialek, R. (1983). *Mol. Cryst. Liq. Cryst.* **100**, 211–221.
- Mandel, P. & Paul, S. (1985). *Mol. Cryst. Liq. Cryst.* **301**, 223–235.
- Manisekaran, T., Bamezai, R. K., Sharma, N. K. & Shashidhara Prasad, J. (1995). *Mol. Cryst. Liq. Cryst.* **268**, 45–50, 83–87.
- Manisekaran, T., Bamezai, R. K., Sharma, N. K. & Shashidhara Prasad, J. (1997). *Liq. Cryst.* **23**, 597–601.
- Molecular Structure Corporation (1992a). *MSCIAFC Diffractometer Control Software*. MSC, 3200 Research Forest Drive, The Woodlands, TX 77381, USA.
- Molecular Structure Corporation (1992b). *TEXSAN. TEXRAY Structure Analysis Package*. MSC, 3200 Research Forest Drive, The Woodlands, TX 77381, USA.
- Sheldrick, G. M. (1985). *SHELXS86. Program for the Solution of Crystal Structures*. University of Göttingen, Germany.
- Sheldrick, G. M. (1993). *SHELXL93. Program for the Refinement of Crystal Structures*. University of Göttingen, Germany.
- Vani, G. V. (1983). *Mol. Cryst. Liq. Cryst.* **99**, 21–27.
- Acta Cryst.* (1998). **C54**, 1477–1479

Complex of (–)-Morphine with β -Phenylhydracrylic Acid†

MARTIN LUTZ AND ANTHONY L. SPEK

Bijvoet Center for Biomolecular Research, Department of Crystal and Structural Chemistry, Utrecht University, Padualaan 8, NL-3584 CH Utrecht, The Netherlands.
E-mail: m.lutz@chem.uu.nl

(Received 23 February 1998; accepted 3 April 1998)

Abstract


The crystal structure of the complex of (–)-morphine with (*S*)- β -phenylhydracrylic acid, $C_{17}H_{20}NO_3 \cdot C_9H_9O_3^-$, is reported. There are no major differences in the conformation of the piperidine ring of morphine compared with other protonated morphines. The staggered conformation of the central bond in the free form of β -phenylhydracrylic acid changes to another staggered conformation in the morphine complex. This conformational change is induced by intermolecular hydrogen bonds.

Comment

Morphine is the most important component of *papaver somniferum* extracts, which have been used as pain-alleviating medicine since ancient times. From a chemical point of view, morphine would be an interesting agent for resolving stereoisomers, but its

† Systematic names: (5 α ,6 α)-7,8-didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol (CAS-No. 57-27-2) and (*S*)-3-hydroxy-3-phenylpropanoic acid (CAS-No. 36567-72-3).

use for this purpose is nearly impossible because of the controlled distribution of this drug. In the present study, we investigate the interaction of morphine with a β -hydroxycarboxylic acid, namely, β -phenylhydracrylic acid. Because of the limited knowledge of the morphine receptor interaction, it is interesting to determine the conformational changes induced by hydrogen-bonding interactions with morphine.



The title compound, (I), with the numbering scheme, is shown in Fig. 1. The carboxy group of the β -phenylhydracrylic acid is deprotonated and the amino group of morphine is protonated. The morphine and acid molecules are linked by hydrogen bonds. Both hydroxy groups of morphine act as hydrogen-bond donors, with the carboxy and hydroxy groups of the same acid anion as the acceptors. The carboxy group is an acceptor for a hydrogen bond from a translated morphine molecule (at $x, y+1, z-1$), with the amino group as donor. The hydroxy group of the acid is the donor in a hydrogen bond to a third morphine molecule (at $x-1, y, z$), with the phenolic group as the acceptor. This pattern of hydrogen bonding builds up a two-dimensional network with $[01\bar{1}]$ and $[100]$ as the base vectors.




Fig. 1. Displacement ellipsoid (50% probability) plot (PLATON; Spek, 1998) of the title complex.

The physiological effectiveness of morphine seems mainly dependent on the conformation of the piperidine ring, the stereochemistry at the N atom or the accessibility of the protonated N atom by the receptor (Kolb, 1987). A ring-puckering analysis (Evans & Boeyens, 1989; Spek, 1998) of the piperidine ring of the title compound results in the parameters $Q =$

$0.614(3) \text{ \AA}$, $\theta = 10.4(3)^\circ$ and $\varphi = 89.5(15)^\circ$, which correspond to a chair conformation with a slight deformation towards a twist-boat conformation. These puckering parameters are essentially the same as those found in morphine hydrochloride trihydrate (Gylbert, 1973) and di(morphine) dihydrogensulfate pentahydrate (Wongweichintana *et al.*, 1984). The stereochemistry at the N atom is also the same in all three cases, so that we can state that the stereochemistry of the protonated piperidine ring of morphine is independent of the counter-ions. A comparison with the crystal structure of morphine hydroiodide dihydrate (Mackay & Hodgkin, 1955) cannot be taken into account because of inaccurate geometrical details of that structure.

The β -phenylhydracrylic acid molecule shows a different conformation in the crystal structure of the morphine complex compared with its conformation in the free form (Cesario & Guilhem, 1974). Not only has the conformation of the carboxy group changed, as would be expected from the different hydrogen-bonding pattern, but the conformation about the central $C_\alpha-C_\beta$ bond has also changed dramatically, by about 120° . MNDO (Dewar & Thiel, 1977) calculations show that the rotational barrier for this bond is quite low ($3.3 \text{ kcal mol}^{-1}$; $1 \text{ kcal mol}^{-1} = 4.184 \text{ kJ mol}^{-1}$), with the three staggered conformations at energy minima. The energy difference between these minima is only $1.1 \text{ kcal mol}^{-1}$. We can therefore assume that the barrier between the staggered conformation of the free compound and the staggered conformation of the morphine complex can be easily overcome by different hydrogen-bonding patterns.

Experimental

Crystals were obtained by slow evaporation of a 1:1 solution of (-)-morphine and (S)- β -phenylhydracrylic acid in water.

Crystal data

$C_{17}H_{20}NO_3^+ \cdot C_9H_9O_3^-$

$M_r = 451.50$

Triclinic

P1

$a = 6.6977(7) \text{ \AA}$

$b = 7.9438(5) \text{ \AA}$

$c = 10.8100(13) \text{ \AA}$

$\alpha = 72.643(8)^\circ$

$\beta = 85.549(9)^\circ$

$\gamma = 88.011(7)^\circ$

$V = 547.26(9) \text{ \AA}^3$

$Z = 1$

$D_x = 1.370 \text{ Mg m}^{-3}$

D_m not measured

Mo $K\alpha$ radiation

$\lambda = 0.71073 \text{ \AA}$

Cell parameters from 25

reflections

$\theta = 9.72\text{--}14.09^\circ$

$\mu = 0.097 \text{ mm}^{-1}$

$T = 293(2) \text{ K}$

Block

$0.30 \times 0.25 \times 0.25 \text{ mm}$

Brown

Data collection

Enraf-Nonius CAD-4T
diffractometer

$R_{int} = 0.091$

$\theta_{max} = 27.49^\circ$

$\omega/2\theta$ scans
Absorption correction: none
4473 measured reflections
4325 independent reflections
3016 reflections with
 $I > 2\sigma(I)$

$h = -8 \rightarrow 8$
 $k = -10 \rightarrow 10$
 $l = -14 \rightarrow 14$
3 standard reflections
frequency: 60 min
intensity decay: 1.1%

Refinement

Refinement on F^2
 $R[F^2 > 2\sigma(F^2)] = 0.051$
 $wR(F^2) = 0.122$
 $S = 1.049$
4325 reflections
314 parameters
H atoms: see below
 $w = 1/[\sigma^2(F_o^2) + (0.0579P)^2 + 0.0076P]$
where $P = (F_o^2 + 2F_c^2)/3$

$(\Delta/\sigma)_{\max} = 0.002$
 $\Delta\rho_{\max} = 0.282 \text{ e } \text{\AA}^{-3}$
 $\Delta\rho_{\min} = -0.211 \text{ e } \text{\AA}^{-3}$
Extinction correction: none
Scattering factors from
International Tables for Crystallography (Vol. C)

Table 1. Selected geometric parameters (\AA , $^\circ$)

N—C17	1.485 (4)	O4—C18	1.240 (4)
N—C16	1.490 (4)	O5—C18	1.255 (4)
N—C9	1.515 (4)		
C17—N—C16	111.1 (2)	C17—N—H1	102 (2)
C17—N—C9	114.0 (2)	C16—N—H1	109 (2)
C16—N—C9	112.8 (2)	C9—N—H1	107 (2)
O4—C18—C19—C20	-118.2 (3)	O6—C20—C21—C22	117.5 (3)
O5—C18—C19—C20	62.1 (4)	C19—C20—C21—C22	-117.3 (3)
C18—C19—C20—O6	175.6 (3)	O6—C20—C21—C26	-63.1 (4)
C18—C19—C20—C21	49.1 (4)	C19—C20—C21—C26	62.1 (4)

Table 2. Hydrogen-bonding geometry (\AA , $^\circ$)

D—H...A	D—H	H...A	D...A	D—H...A
N—H1...O4 ⁱ	0.91 (4)	1.72 (4)	2.620 (3)	171 (3)
O1—H2...O5	0.82 (4)	1.74 (4)	2.535 (3)	166 (4)
O3—H3...O6	0.84 (4)	1.99 (4)	2.775 (4)	156 (4)
O6—H21...O1 ⁱⁱ	0.89 (4)	1.98 (5)	2.820 (4)	155 (4)

Symmetry codes: (i) $x, y - 1, 1 + z$; (ii) $x - 1, y, z$.

The enantiomorph was chosen with respect to the known stereochemistry of (–)-morphine. R_{int} is based on only 148 reflections; if Friedel pairs are merged, $R_{\text{int}} = 0.0495$. All H atoms were located in a difference electron-density map. The positions of the ammonium and hydroxy H atoms were allowed to refine with individual isotropic displacement parameters. All other H atoms were constrained to ride on their parent atoms with $U_{\text{iso}}(\text{H}) = 1.2U_{\text{eq}}(\text{C})$ [$1.5U_{\text{eq}}(\text{C})$ for methyl H atoms].

Data collection: locally modified *CAD-4 Software* (Enraf-Nonius, 1989). Cell refinement: *SET4* (de Boer & Duisenberg, 1984). Data reduction: *HELENA* (Spek, 1997). Program(s) used to solve structure: *SIR97* (Altomare *et al.*, 1997). Program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997). Molecular graphics: *PLATON* (Spek, 1998). Software used to prepare material for publication: *PLATON*.

Crystals were kindly provided by Dr A. Alberts, Technical University of Eindhoven, The Netherlands. The investigations were supported by the Netherlands Foundation for Chemical Research (SON), with financial aid from the Netherlands Organization of Scientific Research (NWO).

Supplementary data for this paper are available from the IUCr electronic archives (Reference: LN1054). Services for accessing these data are described at the back of the journal.

References

- Altomare, A., Cascarano, C., Giacovazzo, C., Guagliardi, A., Moliterni, A. G. G., Burla, M. C., Polidori, G., Camalli, M. & Spagna, R. (1997). *SIR97. A Package for Crystal Structure Solution by Direct Methods and Refinement*. University of Bari, Italy.
- Boer, J. L. de & Duisenberg, A. J. M. (1984). *Acta Cryst.* **A40**, C-410.
- Cesario, M. & Guilhem, J. (1974). *Cryst. Struct. Commun.* **3**, 123–126.
- Dewar, M. J. S. & Thiel, W. (1977). *J. Am. Chem. Soc.* **99**, 4899–4907.
- Enraf-Nonius (1989). *CAD-4 Software*. Version 5.0. Enraf-Nonius, Delft, The Netherlands.
- Evans, D. G. & Boeyens, J. C. A. (1989). *Acta Cryst.* **B45**, 581–590.
- Gylbert, L. (1973). *Acta Cryst.* **B29**, 1630–1635.
- Kolb, V. M. (1987). *Advances in Drug Research*, Vol. 16, edited by B. Testa, pp. 281–307. London: Academic Press.
- Mackay, M. & Hodgkin, D. C. (1955). *J. Chem. Soc.* pp. 3261–3267.
- Sheldrick, G. M. (1997). *SHELXL97. Program for the Refinement of Crystal Structures*. University of Göttingen, Germany.
- Spek, A. L. (1997). *HELENA. Program for Data Reduction*. Utrecht University, The Netherlands.
- Spek, A. L. (1998). *PLATON. Program for the Analysis of Molecular Geometry*. Utrecht University, The Netherlands.
- Wongweichintana, C., Holt, E. M. & Purdie, N. (1984). *Acta Cryst.* **C40**, 1486–1490.

Acta Cryst. (1998). **C54**, 1479–1481

N,N'-Bis(2-phenethyl)perylene-3,4:9,10-bis-(dicarboximide)

JIN MIZUGUCHI

Department of Applied Physics, Faculty of Engineering, Yokohama National University, 79-5 Tokiwadai, Hodogaya-ku, 240-8501 Yokohama, Japan. E-mail: mizuj@ed.ynu.ac.jp

(Received 12 January 1998; accepted 15 April 1998)

Abstract

The molecule of the title compound, $\text{C}_{40}\text{H}_{26}\text{N}_2\text{O}_4$, belongs to point group C_i . The perylene ring system is entirely planar, but is not fully delocalized, as shown by the fact that some C—C bonds are significantly longer compared with those of normal aromatic compounds. The phenyl rings at both ends of the molecule are not completely parallel to the plane of the perylene skeleton, but are slightly twisted in the same direction by about $2.7(2)^\circ$.

Comment

N,N'-Bis(2-phenethyl)perylene-3,4:9,10-bis(dicarboximide), (I), is a commercial black pigment based on the